

Patient 1	CD19+ lymphocytes [1]	< 0.1	< 0.1	2.0	3.7	2.0	39.0	< 0.1				
Patient 2	CD19+ lymphocytes	< 0.1	< 0.2	< 0.1	0.2	< 0.1	< 0.1	21.0	40.0	< 0.1		
Patient 3	CD19+ lymphocytes	< 0.1	1.7	1.0	< 0.1	24.0	70.5	145.0	112.6	< 0.1	< 0.1	12.0

0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82

weeks from first Rituximab infusion

R: Rituximab infusion
M: Methotrexate oral weekly (start)

[1]: number of CD19+ lymphocytes (x 10^6/L) in peripheral blood (range 110 - 449)